The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

"Ecstasy" (MDMA) and related drugs are amphetamine derivatives that also have some of the pharmacological properties of mescaline. They have become popular with participants in "raves," because they enhance energy, endurance, sociability and sexual arousal. This vogue among teenagers and young adults, together with the widespread belief that "ecstasy" is a safe drug, has led to a thriving illicit traffic in it. But these drugs also have serious toxic effects, both acute and chronic, that resemble those previously seen with other amphetamines and are caused by an excess of the same sympathomimetic actions for which the drugs are valued by the users. Neurotoxicity to the serotonergic system in the brain can also cause permanent physical and psychiatric problems. A detailed review of the literature has revealed over 87 "ecstasy"-related fatalities, caused by hyperpyrexia, rhabdomyolysis, intravascular coagulopathy, hepatic necrosis, cardiac arrhythmias, cerebrovascular accidents, and drug-related accidents or suicide. The toxic or even fatal dose range overlaps the range of recreational dosage. The available evidence does not yet permit an accurate assessment of the size of the problem presented by the use of these drugs.

[1]  E. Ellinwood,et al.  Cocaine and other stimulants. Actions, abuse, and treatment. , 1988, The New England journal of medicine.

[2]  A. Louis,et al.  Cerebral Vasculitis Associated With Cocaine Abuse or Subarachnoid Hemorrhage?-Reply , 1988 .

[3]  A. Dinan,et al.  2. Hyperpyrexia Associated with Fatal Paramethoxyamphetamine (PMA) Abuse , 1998 .

[4]  Michael J A Parr,et al.  Hyponatraemia and death after “ecstasy” ingestion , 1997, The Medical journal of Australia.

[5]  A. Alciati,et al.  Three cases of delirium after "ecstasy" ingestion. , 1999, Journal of Psychoactive Drugs.

[6]  G. Rutty,et al.  Deaths associated with MBDB misuse , 2000, International Journal of Legal Medicine.

[7]  F. Vollenweider,et al.  Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy Volunteers , 1998, Neuropsychopharmacology.

[8]  J. Mørland,et al.  Toxicity of drug abuse--amphetamine designer drugs (ecstasy): mental effects and consequences of single dose use. , 2000, Toxicology letters.

[9]  J. Henry Ecstasy and the dance of death. , 1992, BMJ.

[10]  R. Veit,et al.  Cardiovascular autonomic dysregulation in users of MDMA (“Ecstasy”) , 1998, Psychopharmacology.

[11]  A S Christophersen,et al.  Amphetamine designer drugs - an overview and epidemiology. , 2000, Toxicology letters.

[12]  N. Lavies,et al.  An overdose of ecstasy , 1992, Anaesthesia.

[13]  A. Cho,et al.  Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. , 1990, The Journal of pharmacology and experimental therapeutics.

[14]  J. Rodés,et al.  Ecstasy: a common cause of severe acute hepatotoxicity. , 1998, Journal of hepatology.

[15]  J. Jaffe,et al.  The complications of 'ecstasy' (MDMA) , 1988, JAMA.

[16]  A. Parrott Human Research on MDMA (3,4-Methylene- dioxymethamphetamine) Neurotoxicity: Cognitive and Behavioural Indices of Change , 2000, Neuropsychobiology.

[17]  R. Byard,et al.  Amphetamine derivative fatalities in South Australia--is "Ecstasy" the culprit? , 1998, The American journal of forensic medicine and pathology.

[18]  K. L. Jansen,et al.  Ecstasy (MDMA) dependence. , 1999, Drug and alcohol dependence.

[19]  M. Morgan Memory deficits associated with recreational use of “ecstasy” (MDMA) , 1999, Psychopharmacology.

[20]  A. Milosevic,et al.  The occurrence of toothwear in users of Ecstasy (3,4-methylenedioxymethamphetamine). , 1998, Community dentistry and oral epidemiology.

[21]  A. Logan,et al.  Survival following ‘Ecstasy’ ingestion with a peak temperature of 42°C , 1993 .

[22]  S. Kish,et al.  Brief Communications Expedited Publication Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user , 2000 .

[23]  D. Mclellan,et al.  Muscle changes in the neuroleptic malignant syndrome , 2000, Journal of clinical pathology.

[24]  R. Loveland,et al.  Bilateral gluteal compartment syndrome after ‘ecstasy’ hyperpyrexia , 2000, Journal of the Royal Society of Medicine.

[25]  Steven B Karch,et al.  The pathology of drug abuse , 1993 .

[26]  R. Glennon,et al.  Initial Characterization of PMMA as a Discriminative Stimulus1 , 1997, Pharmacology Biochemistry and Behavior.

[27]  A. Freemont,et al.  Ecstasy, 3–4 Methylenedioxymethamphetamine (MDMA), a Fatality Associated with Coagulopathy and Hyperthermia , 1991, Journal of the Royal Society of Medicine.

[28]  L. Itti,et al.  Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study , 2000, Psychiatry Research: Neuroimaging.

[29]  R O Bost,et al.  3,4-Methylenedioxymethamphetamine (MDMA) and other amphetamine derivatives. , 1988, Journal of forensic sciences.

[30]  S. Satchell,et al.  Inappropriate antidiuretic hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion. , 1994, British journal of hospital medicine.

[31]  G. Screaton,et al.  Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse , 1992, The Lancet.

[32]  W. Mcglothlin,et al.  LSD revisited. A ten-year follow-up of medical LSD use. , 1971, Archives of general psychiatry.

[33]  Patrick J. O'Donnell,et al.  Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence , 1999, Psychopharmacology.

[34]  R. de la Torre,et al.  Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. , 1999, The Journal of pharmacology and experimental therapeutics.

[35]  M. Conner,et al.  Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. , 1999, Journal of accident & emergency medicine.

[36]  T. Lukaszewski 3,4-methylenedioxyamphetamine overdose. , 1979, Clinical toxicology.

[37]  A. Poklis,et al.  Distribution of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning. , 1996, Forensic science international.

[38]  J. A. Henry,et al.  Subarachnoid haemorrhage associated with MDMA abuse. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[39]  F. Peters,et al.  Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). , 2000, Toxicology letters.

[40]  A. Poklis,et al.  Fatal intoxication from 3,4-methylenedioxyamphetamine. , 1979, Journal of Forensic Sciences.

[41]  N. Benowitz,et al.  Environmental and drug-induced hyperthermia. Pathophysiology, recognition, and management. , 1984, Emergency medicine clinics of North America.

[42]  M. Morgan Recreational Use of “Ecstasy” (MDMA) Is Associated with Elevated Impulsivity , 1998, Neuropsychopharmacology.

[43]  T. Tena,et al.  Amphetamine derivative related deaths. , 1997, Forensic science international.

[44]  U. McCann,et al.  Adverse Reactions with 3,4-Methylenedioxymethamphetamine (MDMA; ‘Ecstasy’) , 1996, Drug safety.

[45]  B. Synek,et al.  Death from hyponatraemia-induced cerebral oedema associated with MDMA ("Ecstasy") use. , 1999, The New Zealand medical journal.

[46]  J. Henry,et al.  Fatal interaction between ritonavir and MDMA , 1998, The Lancet.

[47]  J. Fisk,et al.  Working memory deficits in current and previous users of MDMA ('ecstasy'). , 2000, British journal of psychology.

[48]  U. McCann,et al.  (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals , 2000, Neuropsychobiology.

[49]  B. Rumack,et al.  Methylenedioxyamphetamine. Clinical description of overdose, death, and review of pharmacology. , 1981, Archives of internal medicine.

[50]  S. Pallanti,et al.  MDMA (Ecstasy) precipitation of panic disorder , 1992, Biological Psychiatry.

[51]  C. Hyde,et al.  ‘Ecstasy’ Psychosis and Flashbacks , 1991, British Journal of Psychiatry.

[52]  I. Leopold,et al.  Pharmacology and toxicology. , 1951, A.M.A. archives of ophthalmology.

[53]  W. Hall,et al.  VIEWPOINT Viewpoint , 2022 .

[54]  J. Jankovic,et al.  Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. , 1996, Clinical neuropharmacology.

[55]  R. Bost,et al.  'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. , 1987, JAMA.

[56]  L. Mair,et al.  An association between the regular use of 3,4 methylenedioxy-methamphetamine (ecstasy) and excessive wear of the teeth. , 1998, Addiction.

[57]  Jörg Daumann,et al.  High Intensity Dependence of Auditory Evoked Dipole Source Activity Indicates Decreased Serotonergic Activity in Abstinent Ecstasy (MDMA) Users , 2000, Neuropsychopharmacology.

[58]  G. Cimbura 3,4-methylenedioxyamphetamine (MDA): analytical and forensic aspects of fatal poisoning. , 1972, Journal of forensic sciences.

[59]  M. Bourin,et al.  3,4-Methylenedioxy analogues of amphetamine: Defining the risks to humans , 1999, Neuroscience & Biobehavioral Reviews.

[60]  R. Glennon,et al.  MDMA Stimulus Generalization to the 5-HT1A Serotonin Agonist 8-Hydroxy-2- (di-n-propylamino)tetralin , 2000, Pharmacology Biochemistry and Behavior.

[61]  M. Polkey,et al.  Hyponatraemia and catatonic stupor after taking "ecstasy". , 1993, BMJ.

[62]  S. Walton,et al.  Cutaneous vasculitis due to ciprofloxacin. , 1992, BMJ.

[63]  R. Clark,et al.  Drug-induced hyperthermia. , 1997, Critical care clinics.

[64]  C. C. Smith,et al.  Ecstasy induced hepatitis mimicking viral hepatitis. , 1995, Gut.

[65]  R. de Silva,et al.  ‘Ecstasy’ and Intracerebral Haemorrhage , 1992, Scottish medical journal.

[66]  T. Ernst,et al.  Cerebral 1H MRS alterations in recreational 3,4‐methylenedioxymethamphetamine (MDMA, “ecstasy”) users , 1999, Journal of magnetic resonance imaging : JMRI.

[67]  I. Sachs,et al.  The action of some amines related to adrenaline: methoxy‐phenylisopropylamines , 1939, The Journal of physiology.

[68]  M. M. Taylor,et al.  Assessment of the MDA and MDMA Optical Isomers in a Stimulant-Hallucinogen Discrimination , 1997, Pharmacology Biochemistry and Behavior.

[69]  P. Rothwell,et al.  Cerebral venous sinus thrombosis induced by 'ecstasy'. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[70]  R. de la Torre,et al.  Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. , 1999, Life sciences.

[71]  J. S. Armstrong,et al.  Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine ("ecstasy") usage. , 1995, Journal of clinical gastroenterology.

[72]  J. Osterloh,et al.  Multiple severe complications from recreational ingestion of MDMA ('Ecstasy') , 1987, JAMA.

[73]  M. Bohnert,et al.  Lethal monointoxication by overdosage of MDEA. , 1998, Forensic science international.

[74]  J. Cadet,et al.  Invited Review Free radicals and the pathobiology of brain dopamine systems , 1998, Neurochemistry International.

[75]  A. Forsyth,et al.  Musical preference as an indicator of adolescent drug use. , 1997, Addiction.

[76]  J. Catalan,et al.  Screening for HIV in pregnancy , 1994, BMJ.

[77]  E. Sellers,et al.  Interactions of amphetamine analogs with human liver CYP2D6. , 1997, Biochemical pharmacology.

[78]  M. D. Schechter MDMA as a discriminative stimulus: Isomeric comparisons , 1987, Pharmacology Biochemistry and Behavior.

[79]  R. K. Siegel,et al.  MDMA. Nonmedical use and intoxication. , 1986, Journal of psychoactive drugs.

[80]  J. C. Borondo,et al.  Intentional overdose and death with 3,4-methylenedioxyethamphetamine (MDEA; "Eve"): case report. , 1998, The American journal of forensic medicine and pathology.

[81]  D. Sweeney,et al.  ECSTACY: A Review of MDMA and MDA , 1987, International journal of psychiatry in medicine.

[82]  Jones,et al.  Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications , 1999, Alimentary pharmacology & therapeutics.

[83]  J. Coakley,et al.  Exertional heat stroke induced by amphetamine analogues , 1993, Anaesthesia.

[84]  F. Vollenweider,et al.  Acute psychological and physiological effects of MDMA (“Ecstasy”) after haloperidol pretreatment in healthy humans , 2000, European Neuropsychopharmacology.

[85]  U. McCann,et al.  Memory impairment in abstinent MDMA ("Ecstasy") users , 1998, Neurology.

[86]  A. Oyefeso,et al.  "Saturday night fever": ecstasy related problems in a London accident and emergency department. , 1998, Journal of accident & emergency medicine.

[87]  A. Walubo,et al.  Fatal multi-organ failure after suicidal overdose with MDMA, `Ecstasy': case report and review of the literature , 1999, Human & experimental toxicology.

[88]  Z. Szabo,et al.  Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). , 2000, Toxicology letters.

[89]  F. Schifano,et al.  MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. , 1998, Drug and alcohol dependence.

[90]  R. Evans,et al.  Intracranial haemorrhage associated with ingestion of 'ecstasy'. , 1993, Archives of emergency medicine.

[91]  J. Cocores,et al.  Neuropsychiatric manifestations following the use of 3, 4-methylenedioxymethamphetamine (MDMA; “Ecstasy”) , 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[92]  Z. Kruk,et al.  Direct effects of 3,4‐methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphé nucleus slices , 2000, Synapse.

[93]  C. Long,et al.  Traffic fatality related to the use of methylenedioxymethamphetamine. , 1996, Journal of forensic sciences.

[94]  R. Riemersma,et al.  "Ecstasy" and sudden cardiac death. , 1988, The American journal of forensic medicine and pathology.

[95]  R. Cohen Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; “Ecstasy”) , 1996, Biological Psychiatry.

[96]  W. van den Brink,et al.  Memory disturbances in ”Ecstasy” users are correlated with an altered brain serotonin neurotransmission , 2000, Psychopharmacology.

[97]  G. Greer,et al.  Subjective reports of the effects of MDMA in a clinical setting. , 1986, Journal of psychoactive drugs.

[98]  A. Forrest,et al.  A fatal overdose with 3,4-methylenedioxyamphetamine derivatives. , 1994, Forensic science international.

[99]  A. Skrondal,et al.  Ecstasy and new patterns of drug use: a normal population study. , 1999, Addiction.

[100]  S. Dawling,et al.  Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") , 1992, The Lancet.

[101]  F. Schifano Potential Human Neurotoxicity of MDMA (‘Ecstasy’): Subjective Self-Reports, Evidence from an Italian Drug Addiction Centre and Clinical Case Studies , 2000, Neuropsychobiology.

[102]  Hans Leysieffer,et al.  Totally implantable hearing device for sensorineural hearing loss , 1998, The Lancet.

[103]  A. Logan,et al.  Survival following 'Ecstasy' ingestion with a peak temperature of 42 degrees C. , 1993, Anaesthesia.

[104]  S. Peroutka,et al.  Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[105]  U. McCann,et al.  Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users. , 1991, Journal of clinical psychopharmacology.

[106]  S. Gore Fatal uncertainty: death-rate from use of ecstasy or heroin , 1999, The Lancet.

[107]  G. Gerra,et al.  Serotonergic function after (±)3,4‐methylene-dioxymethamphetarnine (‘Ecstasy’) in humans , 1998, International clinical psychopharmacology.

[108]  H. Kalant,et al.  Death in amphetamine users: causes and rates. , 1975, Canadian Medical Association journal.

[109]  D. Hilton‐Jones,et al.  Death after ecstasy ingestion: neuropathological findings. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[110]  C. Magee,et al.  Hyponatraemia, seizures and stupor associated with ecstasy ingestion in a female. , 1998, Irish medical journal.

[111]  A. Hölscher,et al.  Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy , 1997, Transplant international : official journal of the European Society for Organ Transplantation.

[112]  G. Hanson,et al.  Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. , 1988, The Journal of pharmacology and experimental therapeutics.

[113]  E. Gouzoulis-Mayfrank,et al.  Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) , 2000, Journal of neurology, neurosurgery, and psychiatry.

[114]  F. Bochner,et al.  The agony of “ecstasy” , 1997, The Medical journal of Australia.

[115]  C. Humpel,et al.  MDMA (‘ecstasy’) enhances basal acetylcholine release in brain slices of the rat striatum , 2000, The European journal of neuroscience.

[116]  V. Williams,et al.  Ecstasy intoxication: appreciation of complications and the role of dantrolene , 1993, Anaesthesia.

[117]  D. E. Cox,et al.  "ADAM' or "EVE'?--a toxicological conundrum. , 1996, Forensic science international.

[118]  Elie,et al.  Auxiliary liver transplantation: Regeneration of the native liver and outcome in 30 patients with fulminant hepatic failure–a multicenter European study , 1996, Hepatology.

[119]  M.D.M.A. (“Ecstasy”); a case of possible drug-induced psychosis , 1993, Irish journal of medical science.

[120]  R. Schwartz,et al.  Accidental ingestion of 'Ecstasy' (3,4-methylenedioxymethylamphetamine). , 1992, Archives of disease in childhood.

[121]  R. Cohen Subjective reports on the effects of the MDMA (‘ecstasy’) experience in humans , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[122]  R. Prouty,et al.  Tissue distribution of methylenedioxymethamphetamine. , 1992, Journal of analytical toxicology.

[123]  G. Beitia,et al.  3,4-Methylenedioxymethamphetamine (ecstasy)-induced hepatotoxicity: effect on cytosolic calcium signals in isolated hepatocytes. , 1999, Liver.

[124]  Y. Shaham,et al.  Serotonin Neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): A Controlled Study in Humans , 1994, Neuropsychopharmacology.

[125]  P D Mueller,et al.  Death by "ecstasy": the serotonin syndrome? , 1998, Annals of emergency medicine.

[126]  R. D. de Man,et al.  [Acute liver failure caused by methylenedioxymethamphetamine ('ecstasy')]. , 1993, Nederlands tijdschrift voor geneeskunde.

[127]  Bill Bynum,et al.  Ecstasy , 2003, The Lancet.

[128]  B. Wilkins Hyponatraemia must be treated with low water input , 1996, BMJ.

[129]  U. Davies,et al.  Landmarks for the insertion of oesophageal endoprosthesis. , 1992 .

[130]  A. Bodenham,et al.  Hyperthermia associated with 3,4‐methylenedioxyethamphetamine (‘Eve’) , 1993, Anaesthesia.

[131]  F. X. Vollenweider,et al.  Notfälle bei Drogenmissbrauch , 2000, Der Internist.

[132]  M. Colado,et al.  The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, "eve") on body temperature and long term degeneration of 5-HT neurones in brain: a comparison with MDMA ("ecstasy"). , 1999, Pharmacology & toxicology.

[133]  R. de la Torre,et al.  Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. , 2000, British journal of clinical pharmacology.

[134]  W. Alexander,et al.  Hyponatraemia and seizures after ecstasy use , 1999, Postgraduate medical journal.

[135]  D. Dietrich,et al.  Emotion/cognition-coupling in word recognition memory of depressive patients: an event-related potential study , 2000, Psychiatry Research.

[136]  A. Forrest,et al.  Pathology of deaths associated with "ecstasy" and "eve" misuse. , 1996, Journal of clinical pathology.

[137]  M J Connolly,et al.  Cerebral infarction in association with Ecstasy abuse. , 1993, Postgraduate medical journal.

[138]  J. Coore,et al.  A Fatal Trip with Ecstasy: A Case of 3,4-Methylene-Dioxymethamphetamine/ 3,4-Methylenedioxy-Amphetamine Toxicity , 1996, Journal of the Royal Society of Medicine.

[139]  R. Buchert,et al.  Ecstasy – long-term effects on the human central nervous system revealed by positron emission tomography , 1999, British Journal of Psychiatry.

[140]  A. Schmoldt,et al.  Two very different fatal cases associated with the use of methylenedioxyethylamphetamine (MDEA): Eve as deadly as Adam. , 1996, Journal of toxicology. Clinical toxicology.

[141]  L. Seiden,et al.  Small Changes in Ambient Temperature Cause Large Changes in 3,4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonin Neurotoxicity and Core Body Temperature in the Rat , 1998, The Journal of Neuroscience.

[142]  J. Spatt,et al.  A pure amnestic syndrome after MDMA ("ecstasy") ingestion. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[143]  W. Modell The Amphetamines: Toxicity and Addiction , 1967 .

[144]  B. Schroeder,et al.  Bilateral sixth nerve palsy associated with MDMA ("ecstasy") abuse. , 2000, American journal of ophthalmology.

[145]  P. McGuire,et al.  Diversity of Psychopathology Associated with use of 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) , 1994, British Journal of Psychiatry.

[146]  A. Jacks,et al.  Retinal haemorrhage caused by “ecstasy” , 1998, British Journal of Ophthalmology.

[147]  K. Druschky,et al.  Grand-mal-Serie nach Ecstasy-Einnahme , 1999, Der Nervenarzt.

[148]  G. Cimbura PMA deaths in Ontario. , 1974, Canadian Medical Association journal.

[149]  R. H. Cravey,et al.  A fatal case involving methylenedioxyamphetamine. , 1972, Clinical toxicology.

[150]  R. de Silva,et al.  Misuse of ecstasy. , 1992, BMJ.

[151]  A. Burroughs,et al.  Chronic ecstasy (3,4-methylenedioxymetamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. , 1996, Journal of hepatology.

[152]  D. Murphy,et al.  Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users , 1999, Psychopharmacology.

[153]  B. Kessel Hyponatraemia after ingestion of “ectasy” , 1994 .

[154]  D. N. Sims,et al.  Recent paramethoxyamphetamine deaths. , 1998, Journal of analytical toxicology.

[155]  A. Shulgin The background and chemistry of MDMA. , 1986, Journal of psychoactive drugs.

[156]  J. Sills,et al.  Cerebral oedema after ingestion of MDMA (“ecstasy”) and unrestricted intake of water , 1996, BMJ.

[157]  D. Nichols,et al.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. , 1986, Journal of psychoactive drugs.

[158]  E. Gouzoulis-Mayfrank,et al.  [Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?]. , 1996, Der Nervenarzt.

[159]  G. D. den Heeten,et al.  MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. , 2000, AJNR. American journal of neuroradiology.

[160]  E. Turillazzi,et al.  Adam (MDMA) and Eve (MDEA) misuse: an immunohistochemical study on three fatal cases. , 1999, Forensic science international.

[161]  H. Curran,et al.  Is MDMA (‘Ecstasy’) Neurotoxic in Humans? An Overview of Evidence and of Methodological Problems in Research , 2000, Neuropsychobiology.

[162]  Z. Szabo,et al.  Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.

[163]  R. Glennon,et al.  Stereochemistry of the metabolism of MDMA to MDA. , 1989, Life sciences.

[164]  R. Thomasius,et al.  [MDMA ("Ecstasy") use--an overview of psychiatric and medical sequelae]. , 1997, Fortschritte der Neurologie-Psychiatrie.

[165]  A. Parrott,et al.  Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. , 2000, Drug and alcohol dependence.

[166]  J. Knochel,et al.  Rhabdomyolysis and shock after intravenous amphetamine administration. , 1977, Annals of internal medicine.

[167]  F. Vollenweider,et al.  Acute Psychological Effects of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) are Attenuated by the Serotonin Uptake Inhibitor Citalopram , 1999, Neuropsychopharmacology.

[168]  S. Hickenbottom,et al.  Parkinsonism after taking ecstasy. , 1999, The New England journal of medicine.

[169]  M. Ginsberg,et al.  Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure. A syndrome resembling heatstroke. , 1970, Annals of internal medicine.

[170]  B. Portmann,et al.  Acute liver damage and ecstasy ingestion. , 1996, Gut.

[171]  U. McCann,et al.  (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical Studies , 2000, Neuropsychobiology.

[172]  K. Kovar,et al.  Screening experiments of ecstasy street samples using near infrared spectroscopy. , 1999, Forensic science international.

[173]  R. Holden,et al.  Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA) , 1996, The Lancet.

[174]  A. Parrott,et al.  Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance , 1998, Psychopharmacology.

[175]  Nicki Bradley BMJ should use “paracetamol” instead of “acetaminophen” in its index , 1996, BMJ.

[176]  Leif Bjermer,et al.  Airway hyperresponsiveness to methacholine, adenosine 5-monophosphate, mannitol, eucapnic voluntary hyperpnoea and field exercise challenge in elite cross-country skiers , 2010, British Journal of Sports Medicine.

[177]  G. Gerra,et al.  Long-lasting effects of (±)3,4-methylene-dioxymethamphetamine (Ecstasy) on serotonin system function in humans , 2000, Biological Psychiatry.

[178]  P. McGuire Long term psychiatric and cognitive effects of MDMA use. , 2000, Toxicology letters.

[179]  Klaus P. Ebmeier,et al.  Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users , 1999, British Journal of Psychiatry.